InnoCare Pharma announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for the Company's B-cell lymphoma-2 (BCL2) inhibitor, ICP-248. This is InnoCare's fifth innovative drug to enter the clinical stage in the U.S. This is a Phase I study to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of ICP-248 in hematologic malignancy patients. ICP-248 is a novel, orally bioavailable BCL2-selective inhibitor, which aims to treat hematologic malignancies as a monotherapy or in combination with other therapies.

The Phase I dose escalation trial of ICP-248 is ongoing in China, and the preliminary results demonstrated good efficacy and safety profiles. ICP-248 exhibits its anti-tumor effects by selectively inhibiting BCL2 and restoring the mechanism of programmed cell death.